Compare · MDLN vs PAVM
MDLN vs PAVM
Side-by-side comparison of Medline Inc. (MDLN) and PAVmed Inc. (PAVM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PAVM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $45.60B, about 1276.9x PAVM ($35.7M).
- Over the past year, MDLN is down 13.3% and PAVM is down 72.8% - MDLN leads by 59.5 points.
- MDLN has hit the wire 18 times in the past 4 weeks while PAVM has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 0 for PAVM).
- Company
- Medline Inc.
- PAVmed Inc.
- Price
- $35.33+1.87%
- $5.01+24.63%
- Market cap
- $45.60B
- $35.7M
- 1M return
- -4.69%
- -17.73%
- 1Y return
- -13.30%
- -72.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2016
- News (4w)
- 18
- 0
- Recent ratings
- 25
- 0
PAVmed Inc.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.
Latest MDLN
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P covered exercise/tax liability with 1,889 shares, converted options into 100,000 shares, sold $3,677,115 worth of shares (100,000 units at $36.77) as part of a pre-agreed trading plan and returned 100,000 units of Class B Common Stock to the company, increasing direct ownership by 1,319% to 365,864 units (SEC Form 4)
- Chief Executive Officer Boyle James M covered exercise/tax liability with 2,370 shares, decreasing direct ownership by 7% to 29,369 units (SEC Form 4)
- Director Galanti Richard A was granted 16,392 shares (SEC Form 4)
- Director Sweet Thomas W was granted 17,800 shares (SEC Form 4)
Latest PAVM
- PAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
- SEC Form 10-Q filed by PAVmed Inc.
- SEC Form SCHEDULE 13G filed by PAVmed Inc.
- Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
- SEC Form DEF 14A filed by PAVmed Inc.
- PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
- SEC Form DEFA14A filed by PAVmed Inc.
- Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
- SEC Form EFFECT filed by PAVmed Inc.